Kimball Electronics Q1 2027 earnings
Revenue grew 7% YoY, but operating income and EPS fell sharply due to a large restructuring charge and lower margins.
Headline numbers
| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| Revenue | $390.8M | +7% | — | Ex. 99.1, income statement |
| EPS (GAAP) | $0.11 | -72.5% | — | Ex. 99.1, income statement |
| EPS (adjusted) | $0.25 | -49% | — | Ex. 99.1, income statement |
| Net income | $2.6M | -73.8% | — | Ex. 99.1, income statement |
| Adj. EBITDA | $19.0M | -3.2% | — | Ex. 99.1, income statement |
| Adj. EBITDA margin | 4.3% | -0.5 pp | — | Ex. 99.1, income statement |
Revenue breakdown
| Segment | Actual | YoY | Share of revenue | Note |
|---|---|---|---|---|
| Medical | $108.8M | +1% | 28% | Growth 14% net, 9% organic |
| Automotive | $169.7M | -3% | 43% | — |
| Industrial excluding AT&M | $93.1M | -5% | 24% | — |
Margins and costs
- Gross margin 7.9% (prior 7.9%, change 0.0 pp)
- Operating expenses $18.1M (+38% YoY)
- One-offs in the quarter Restructuring expense $0.4M; Gain on disposal $0M
- Effective tax rate 66% (prior-year 8.3%, year-to-date 66%)
- Non-GAAP bridge Adds back stock compensation, acquisition amortization, and restructuring expense
KPIs
| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Net Sales Growth | 7% | — | -2% | +9 pp |
| Organic Sales Growth | 3% | — | -3% | +6 pp |
| Medical Vertical Net Sales Growth | 14% | — | 13% | +1 pp |
| Medical Vertical Organic Sales Growth | 9% | — | 12% | -3 pp |
Guidance
| Metric | Guide | Prior guide | Change |
|---|---|---|---|
| Net sales | $1,535 - $1,560M | $1,535 - $1,560M | No change |
| Adjusted operating income margin | 4.4% - 4.7% of net sales | 4.4% - 4.7% of net sales | No change |
| Capital expenditures | $50 - $60M | $50 - $60M | No change |
What drove it
- Revenue story Total revenue grew 7% YoY, driven by Medical (+1% total, +14% net) and offset by Automotive (-3%) and Industrial (-5%).
- EPS story GAAP EPS fell due to a 66% tax rate and a $0.4M restructuring charge; adjusted EPS declined due to lower operating margins.
- One-off check Restructuring expense $0.4M (non-GAAP add-back); Gain on disposal $0M
The good
- Medical vertical revenue grew 14% net YoY
- Cash and cash equivalents increased to $72.8M
The bad
- Operating income fell 14% YoY to $12.4M
- Adjusted operating income margin declined 0.5 pp YoY to 4.3%
- GAAP net income swung to a loss of $2.6M
The ugly
- none
Open questions
- Why did operating income and adjusted operating income margin decline despite revenue growth?
- What drove the significant increase in the tax rate to 66%?
Full release
Kimball Electronics (KE) earnings release, November 4, 2026
JASPER, Ind., November 4, 2026 -- (BUSINESS WIRE) -- Kimball Electronics, Inc. (Nasdaq: KE) today announced financial results for the first quarter ended September 30, 2026.
FISCAL YEAR 2027 GUIDANCE
As part of today’s announcement, the Company reiterated its guidance for fiscal 2027 with net sales expected at the high end of the range of $1,535 - $1,560 million, adjusted operating income of 4.4% - 4.7% of net sales, and capital expenditures of $50 - $60 million.
Financial statements
Income Statement
Three Months Ended — Financial highlights for the first quarter ended September 30, 2026 are as follows: (Amounts in Thousands, except EPS)
| Three Months Ended – September 30, – 2026 | Three Months Ended – September 30, – 2025 | |
|---|---|---|
| Net Sales | 390,803 | 365,603 |
| Operating Income | 12,374 | 14,454 |
| Adjusted Operating Income (non-GAAP) | 16,990 | 17,534 |
| Operating Income % | 3.2% | 4.0% |
| Adjusted Operating Income (non-GAAP) % | 4.3% | 4.8% |
| Net Income | 2,642 | 10,086 |
| Adjusted Net Income (non-GAAP) | 6,121 | 12,250 |
| Diluted EPS | 0.11 | 0.4 |
| Adjusted Diluted EPS (non-GAAP) | 0.25 | 0.49 |
Income Statement
Fiscal 2027: (Amounts in Thousands, except Per Share Data)
| Condensed Consolidated Statements of Income – Three Months Ended – September 30, 2026 | Three Months Ended – September 30, 2026 | Three Months Ended – September 30, 2025 | Three Months Ended – September 30, 2025 | |
|---|---|---|---|---|
| Net Sales | 390,803 | 100 | 365,603 | 100 |
| Cost of Sales | 359,929 | 92.1 | 336,767 | 92.1 |
| Gross Profit | 30,874 | 7.9 | 28,836 | 7.9 |
| Selling and Administrative Expenses | 18,055 | 4.6 | 13,090 | 3.5 |
| Restructuring Expense | 445 | 0.1 | 1,416 | 0.4 |
| Gain on Disposal | -124 | |||
| Operating Income | 12,374 | 3.2 | 14,454 | 4 |
| Interest Income | 549 | 0.1 | 139 | |
| Interest Expense | -3,519 | -0.9 | -2,353 | -0.6 |
| Non-Operating Income (Expense), net | -1,601 | -0.4 | -1,241 | -0.4 |
| Other Income (Expense), net | -4,571 | -1.2 | -3,455 | -1 |
| Income Before Taxes on Income | 7,803 | 2 | 10,999 | 3 |
| Provision (Benefit) for Income Taxes | 5,161 | 1.3 | 913 | 0.2 |
| Net Income | 2,642 | 0.7 | 10,086 | 2.8 |
| Earnings Per Share of Common Stock: | ||||
| Basic | 0.11 | 0.41 | ||
| Diluted | 0.11 | 0.4 | ||
| Average Number of Shares Outstanding: | ||||
| Basic | 24,330 | 24,600 | ||
| Diluted | 24,581 | 24,909 | ||
Income Statement
Open Orders are the aggregate sales price of production pursuant to unfulfilled customer orders. (Unaudited, Amounts in Thousands, except Per Share Data)
| Three Months Ended – September 30, – 2026 | Three Months Ended – September 30, – 2025 | |
|---|---|---|
| (Unaudited, Amounts in Thousands, except Per Share Data) | ||
| Net Sales Growth (vs. same period in prior year) | 7 | -2 |
| Acquisition Impact | 3 | |
| Foreign Currency Exchange Impact | 1 | 1 |
| Organic Sales Growth | 3 | -3 |
| Net Sales Growth (vs. same period in prior year), Medical Vertical | 14 | 13 |
| Acquisition Impact, Medical Vertical | 5 | |
| Foreign Currency Exchange Impact, Medical Vertical | 1 | |
| Organic Sales Growth, Medical Vertical | 9 | 12 |
| Stock Compensation Expense | ||
| SERP | 14 | -225 |
| Acquisition Amortization | -532 | |
| SERP | -14 | 225 |
| Restructuring Expense | 445 | |
| Asset Impairment (Gain on Disposal) | -124 | |
| Acquisition Amortization | 532 | |
| Stock Compensation Expense, After-Tax | ||
| Restructuring Expense, After-Tax | 312 | |
| Asset Impairment (Gain on Disposal), After-Tax | -94 | |
| Acquisition Amortization, After-Tax | 396 | |
| Diluted Earnings per Share, as reported | ||
| Stock Compensation Expense | 0.05 | 0.05 |
| Restructuring Expense | 0.01 | 0.04 |
| Acquisition Amortization | 0.02 | |
| Acquisition Costs | 0.06 | |
Balance Sheet
Fiscal 2027:
| (Unaudited) – September 30, 2026 | June 30, 2026 | |
|---|---|---|
| ASSETS | ||
| Cash and cash equivalents | 72,763 | 88,925 |
| Receivables, net | 236,068 | 218,840 |
| Contract assets | 83,003 | 70,497 |
| Inventories | 312,137 | 271,906 |
| Prepaid expenses and other current assets | 49,371 | 42,836 |
| Property and Equipment, net | 304,480 | 274,192 |
| Goodwill | 50,459 | 6,191 |
| Other Intangible Assets, net | 25,491 | 1,921 |
| Other Assets, net | 103,426 | 116,762 |
| Total Assets | 1,237,198 | 1,092,070 |
| LIABILITIES AND SHARE OWNERS’ EQUITY | ||
| Current portion of long-term debt | 39,700 | 8,202 |
| Accounts payable | 260,560 | 234,361 |
| Advances from customers | 36,607 | 30,672 |
| Accrued expenses | 58,725 | 58,860 |
| Long-term debt, less current portion | 195,650 | 108,000 |
| Other long-term liabilities | 63,739 | 66,843 |
| Share Owners’ Equity | 582,217 | 585,132 |
| Total Liabilities and Share Owners’ Equity | 1,237,198 | 1,092,070 |
Cash Flow
Condensed Consolidated Statements of Cash Flows — Fiscal 2027: (in thousands)
| Three Months Ended – September 30, – 2026 | Three Months Ended – September 30, – 2025 | |
|---|---|---|
| Net Cash Flow provided by (used for) Operating Activities | -19,324 | 8,065 |
| Net Cash Flow used for Investing Activities | -109,728 | -6,202 |
| Net Cash Flow provided by (used for) Financing Activities | 114,026 | -13,966 |
| Effect of Exchange Rate Change on Cash, Cash Equivalents, and Restricted Cash | -64 | 116 |
| Net Decrease in Cash, Cash Equivalents, and Restricted Cash | -15,090 | -11,987 |
| Cash, Cash Equivalents, and Restricted Cash at Beginning of Period | 89,641 | 89,467 |
| Cash, Cash Equivalents, and Restricted Cash at End of Period | 74,551 | 77,480 |
Certain statements contained within this release are considered forward-looking, including our guidance, under the Private Securities Litigation Reform Act of 1995. The statements may be identified by the use of words such as “expect,” “should,” “goal,” “predict,” “will,” “future,” “optimistic,” “confident,” and “believe.” Undue reliance should not be placed on these forward-looking statements. These statements are based on current expectations of future events and thus are inherently subject to uncertainty. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. These forward-looking statements are subject to risks and uncertainties including, without limitation, global economic conditions, geopolitical environment and conflicts such as war, global health emergencies, availability or cost of raw materials and components, tariffs and other trade barriers, foreign exchange rate fluctuations, and our ability to convert new business opportunities into customers and revenue. Additional cautionary statements regarding other risk factors that could have an effect on the future performance of the company are contained in its Annual Report on Form 10-K for the year ended June 30, 2026.
This press release contains non-GAAP financial measures. The non-GAAP financial measures contained herein include organic sales growth, adjusted selling and administrative expenses, adjusted operating income, adjusted EBITDA, adjusted net income, and adjusted diluted EPS. Reconciliations of the reported GAAP numbers to these non-GAAP financial measures are included in the Reconciliation of Non-GAAP Financial Measures section below. Management believes these measures are useful and allow investors to meaningfully trend, analyze, and benchmark the performance of the company’s core operations. The company’s non-GAAP financial measures are not necessarily comparable to non-GAAP information used by other companies.
Kimball Electronics is a global, multifaceted manufacturer offering Electronics Manufacturing Services (EMS) and Contract Development and Manufacturing Organization (CDMO) solutions to customers around the world. From our operations in the United States, China, India, Mexico, The Netherlands, Poland, Romania, and Thailand, our teams are proud to provide manufacturing services for a variety of industries. Recognized for a reputation of excellence, we are committed to a high-performance culture that values quality, reliability, value, speed, and ethical behavior. Kimball Electronics, Inc. (Nasdaq: KE) is headquartered in Jasper, Indiana.
To learn more about Kimball Electronics, visit www.kimballelectronics.com.
Lasting relationships. Global success.
Financial highlights for the first quarter ended September 30, 2026 are as follows:
Net Sales by Vertical Market for Q1
Fiscal 2027:
(1)
Cash Conversion Days (“CCD”) are calculated as the sum of Days Sales Outstanding plus Contract Asset Days plus Production Days Supply on Hand less Accounts Payable Days and less Advances from Customers Days. CCD, or a similar metric, is used in our industry and by our management to measure the efficiency of managing working capital.
(2)
Open Orders are the aggregate sales price of production pursuant to unfulfilled customer orders.